08:33 AM EDT, 06/20/2025 (MT Newswires) -- Eli Lilly ( LLY ) is planning to appeal against the UK's National Institute for Health and Care Excellence's, or NICE's, suggestion not to reimburse the cost of Alzheimer's drug Kisunla, Reuters reported Thursday, citing the company.

According to the report, the drugmaker considers the regulator's recommendation to be unreasonable based on the evidence submitted by the company, clinical experts and patient groups.

Neither Lilly nor NICE immediately responded to MT Newswires' request for comment.

Lilly's shares added 0.6% in recent Friday premarket activity.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)